Biocon has announced the successful completion of a Pre-License Inspection (PLI) by the U.S. Food and Drug Administration (FDA) at its biosimilars manufacturing site in Bengaluru, India. The inspection, which concluded on April 29, 2026, spanned three biologics manufacturing units, five quality laboratories, and two warehouses. The company received five procedural observations and remains committed to addressing these findings through a comprehensive corrective plan.
Inspection Overview
The U.S. Food and Drug Administration (FDA) concluded a rigorous Pre-License Inspection at Biocon’s dedicated biosimilars facility located in Biocon Park, Bengaluru. The audit process took place between April 20, 2026, and April 29, 2026, covering critical infrastructure including production units, testing labs, and logistics facilities.
Observations and Next Steps
At the conclusion of the review, the regulatory body issued a Form 483 containing five observations. The company clarified that these observations are procedural in nature and do not indicate issues with data integrity or quality oversight. Furthermore, it was noted that there were no repeat observations identified during this visit.
Commitment to Quality
Biocon has confirmed its intention to submit a comprehensive Corrective and Preventive Action (CAPA) plan within the required timeline. The organization expressed full confidence in its ability to address these observations expeditiously. Biocon continues to emphasize its dedication to maintaining high global standards for product safety, efficacy, and reliability while working in collaboration with regulatory authorities.
Source: BSE
